[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-001", "question": "A 45-year-old with severe ARDS on VV-ECMO develops suspected heparin-induced thrombocytopenia (4T score 6). Heparin is discontinued and argatroban initiated. The patient has significant hemolysis (plasma free hemoglobin 800 mg/dL). Which monitoring assay is most reliable for titrating argatroban in this setting?", "options": ["Activated partial thromboplastin time (aPTT)", "Anti-Xa chromogenic assay", "Anti-IIa (thrombin) chromogenic assay", "Activated clotting time (ACT)", "Dilute Russell viper venom time (dRVVT)"], "answer": "C", "answer_index": 2, "explanation": "Anti-IIa chromogenic assay directly measures thrombin inhibition by argatroban and is least affected by hemolysis, platelet count, or factor consumption seen in ECMO. aPTT is unreliable due to factor deficiency and hemolysis. Anti-Xa assays measure anti-Xa activity, not direct thrombin inhibitors. ACT is affected by platelets and fibrinogen. dRVVT is used for lupus anticoagulant detection.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Patient on VV-ECMO with severe ARDS, suspected HIT, switched to argatroban; significant hemolysis with very high plasma free hemoglobin. Question asks which assay is most reliable for titrating a direct thrombin inhibitor (argatroban) in the context of ECMO-associated coagulopathy and hemolysis.\\nAnti-IIa (thrombin) chromogenic assay specifically measures argatroban’s direct thrombin inhibition and, unlike clot-based assays, is less influenced by hemolysis, thrombocytopenia, factor deficiency, or consumption—thus is the most reliable for dosing. aPTT and ACT are standard bedside tools but are notoriously unreliable in ECMO/HIT because they are affected by factor levels, fibrinogen, platelets, and circuit effects. Anti-Xa assays are specific for heparin/LMWH and do not quantify direct thrombin inhibitors. dRVVT is for lupus anticoagulant and not used for argatroban titration.\\nMain logical issue(s): None; stem clearly points to a direct thrombin inhibitor in a setting where clot-based tests are unreliable, making C uniquely best.\\nMain medical accuracy issue(s): Minor—the claim about being “least affected” is somewhat generalized but directionally correct.\\nMinimal fix: Optionally specify “chromogenic anti-IIa (thrombin) assay calibrated for argatroban” to enhance precision and realism.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Patient on VV-ECMO with severe ARDS, suspected HIT, switched to argatroban; significant hemolysis with very high plasma free hemoglobin. Question asks which assay is most reliable for titrating a direct thrombin inhibitor (argatroban) in the context of ECMO-associated coagulopathy and hemolysis.\nAnti-IIa (thrombin) chromogenic assay specifically measures argatroban’s direct thrombin inhibition and, unlike clot-based assays, is less influenced by hemolysis, thrombocytopenia, factor deficiency, or consumption—thus is the most reliable for dosing. aPTT and ACT are standard bedside tools but are notoriously unreliable in ECMO/HIT because they are affected by factor levels, fibrinogen, platelets, and circuit effects. Anti-Xa assays are specific for heparin/LMWH and do not quantify direct thrombin inhibitors. dRVVT is for lupus anticoagulant and not used for argatroban titration.\nMain logical issue(s): None; stem clearly points to a direct thrombin inhibitor in a setting where clot-based tests are unreliable, making C uniquely best.\nMain medical accuracy issue(s): Minor—the claim about being “least affected” is somewhat generalized but directionally correct.\nMinimal fix: Optionally specify “chromogenic anti-IIa (thrombin) assay calibrated for argatroban” to enhance precision and realism.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-002", "question": "A 62-year-old with metastatic pancreatic adenocarcinoma on gemcitabine presents with acute kidney injury (creatinine 3.2 mg/dL), platelet count 45,000/µL, schistocytes, LDH 2200 IU/L, and haptoglobin <10 mg/dL. ADAMTS13 activity is 35%. What is the most appropriate initial management?", "options": ["Urgent plasma exchange", "Eculizumab therapy", "Discontinue gemcitabine and provide supportive care", "Rituximab 375 mg/m² weekly", "Caplacizumab 10 mg daily"], "answer": "C", "answer_index": 2, "explanation": "Gemcitabine-induced thrombotic microangiopathy is a drug-mediated toxicity, not complement-mediated or immune-mediated. ADAMTS13 is not severely deficient (<10%), excluding TTP. Plasma exchange is ineffective. Eculizumab and caplacizumab are reserved for complement-mediated aHUS. Rituximab is for TTP. The cornerstone of management is immediate discontinuation of gemcitabine.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Metastatic pancreatic adenocarcinoma on gemcitabine; new AKI, thrombocytopenia, MAHA (schistocytes, very high LDH, low haptoglobin); ADAMTS13 activity 35% (i.e., not severely deficient). This is classic for drug-induced thrombotic microangiopathy from gemcitabine. In such cases, the primary and evidence‑based initial management is immediate discontinuation of the offending drug and supportive care; plasma exchange has not shown clear benefit and is not standard for typical gemcitabine‑TMA.\\nEvaluation of alternatives: Plasma exchange (A) is reserved for immune TTP with severe ADAMTS13 deficiency; ADAMTS13 of 35% makes this unlikely. Eculizumab (B) is for complement‑mediated aHUS; no evidence of that here. Rituximab (D) is used in immune TTP or refractory immune etiologies, not drug‑toxicity TMA. Caplacizumab (E) is for acquired severe ADAMTS13‑deficient TTP.\\nMain medical accuracy issues: Minor—some clinicians may trial PLEX early while diagnosis is uncertain, but for a classic gemcitabine‑TMA vignette, discontinuation/support is accepted best initial step.\\nMinimal fix: Explicitly label this as “suspected gemcitabine‑induced thrombotic microangiopathy” in the stem to further reinforce the teaching point.\",\n  \"medical_accuracy_score\":    \"4\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Metastatic pancreatic adenocarcinoma on gemcitabine; new AKI, thrombocytopenia, MAHA (schistocytes, very high LDH, low haptoglobin); ADAMTS13 activity 35% (i.e., not severely deficient). This is classic for drug-induced thrombotic microangiopathy from gemcitabine. In such cases, the primary and evidence‑based initial management is immediate discontinuation of the offending drug and supportive care; plasma exchange has not shown clear benefit and is not standard for typical gemcitabine‑TMA.\nEvaluation of alternatives: Plasma exchange (A) is reserved for immune TTP with severe ADAMTS13 deficiency; ADAMTS13 of 35% makes this unlikely. Eculizumab (B) is for complement‑mediated aHUS; no evidence of that here. Rituximab (D) is used in immune TTP or refractory immune etiologies, not drug‑toxicity TMA. Caplacizumab (E) is for acquired severe ADAMTS13‑deficient TTP.\nMain medical accuracy issues: Minor—some clinicians may trial PLEX early while diagnosis is uncertain, but for a classic gemcitabine‑TMA vignette, discontinuation/support is accepted best initial step.\nMinimal fix: Explicitly label this as “suspected gemcitabine‑induced thrombotic microangiopathy” in the stem to further reinforce the teaching point.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-003", "question": "A 28-year-old presents 2 hours after ingesting barium carbonate with profuse vomiting, diarrhea, and profound muscle weakness. Serum potassium is 2.1 mEq/L with ST-segment depression on ECG. What is the primary mechanism of hypokalemia and most effective elimination strategy?", "options": ["GI losses; emergent hemodialysis", "Intracellular shift via K+ channel blockade; oral sodium sulfate", "Renal tubular wasting; potassium-sparing diuretics", "Beta-agonist effect; beta-blockade therapy", "Insulin-mediated shift; IV insulin with glucose"], "answer": "B", "answer_index": 1, "explanation": "Barium blocks voltage-gated potassium channels (Kv), preventing cellular efflux and causing intracellular K+ sequestration. Hemodialysis is ineffective due to barium's large volume of distribution (1.5 L/kg). Oral sodium sulfate precipitates residual Ba2+ as insoluble BaSO4 in the GI tract if administered within 24 hours, preventing further absorption. Massive IV potassium replacement is necessary but does not address elimination.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Acute ingestion of barium carbonate; rapid onset vomiting/diarrhea plus profound muscle weakness; severe hypokalemia (K+ 2.1 mEq/L) with ECG changes; question explicitly asks for mechanism of hypokalemia and most effective elimination strategy. Barium is known to block voltage-gated K+ channels, causing intracellular sequestration (apparent hypokalemia) rather than primarily GI or renal loss. For elimination, hemodialysis is relatively ineffective because of large volume of distribution and protein binding, whereas early oral sodium sulfate precipitates Ba2+ as insoluble BaSO4, reducing absorption and systemic burden.\\nOption B uniquely matches both components (mechanism and elimination). A (GI losses; hemodialysis) contradicts barium physiology. C (renal wasting; K-sparing diuretics), D (beta-agonist), and E (insulin-mediated shift) are inconsistent with known barium toxicodynamics and do not provide the correct elimination approach.\\nMain medical accuracy issues: Minor—item correctly notes dialysis is relatively ineffective but could acknowledge limited role in massive poisoning.\\nMinimal fix: Add timing qualifier in stem (e.g., “presents 2 hours after ingestion”) already present—item is essentially adequate; optionally specify “most effective GI elimination strategy” to clarify focus on unabsorbed toxin.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Acute ingestion of barium carbonate; rapid onset vomiting/diarrhea plus profound muscle weakness; severe hypokalemia (K+ 2.1 mEq/L) with ECG changes; question explicitly asks for mechanism of hypokalemia and most effective elimination strategy. Barium is known to block voltage-gated K+ channels, causing intracellular sequestration (apparent hypokalemia) rather than primarily GI or renal loss. For elimination, hemodialysis is relatively ineffective because of large volume of distribution and protein binding, whereas early oral sodium sulfate precipitates Ba2+ as insoluble BaSO4, reducing absorption and systemic burden.\nOption B uniquely matches both components (mechanism and elimination). A (GI losses; hemodialysis) contradicts barium physiology. C (renal wasting; K-sparing diuretics), D (beta-agonist), and E (insulin-mediated shift) are inconsistent with known barium toxicodynamics and do not provide the correct elimination approach.\nMain medical accuracy issues: Minor—item correctly notes dialysis is relatively ineffective but could acknowledge limited role in massive poisoning.\nMinimal fix: Add timing qualifier in stem (e.g., “presents 2 hours after ingestion”) already present—item is essentially adequate; optionally specify “most effective GI elimination strategy” to clarify focus on unabsorbed toxin.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-004", "question": "A 3-month-old infant presents with intractable seizures, hypotonia, and developmental regression. Brain MRI shows bilateral globus pallidus hyperintensity. Plasma creatine level is low. Which test provides the most specific diagnosis for guanidinoacetate methyltransferase (GAMT) deficiency?", "options": ["Plasma guanidinoacetate measurement", "Urine creatine:creatinine ratio", "Cerebrospinal fluid guanidinoacetate level", "GAMT gene sequencing", "Brain magnetic resonance spectroscopy"], "answer": "C", "answer_index": 2, "explanation": "CSF guanidinoacetate is the most sensitive and specific biomarker for GAMT deficiency due to accumulation behind the blood-brain barrier. Plasma GAA can be normal in mild cases. Urine ratio is supportive but nonspecific. GAMT sequencing may miss deep intronic variants or large deletions. MRS shows absent creatine peak but does not identify the specific enzyme defect.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed – D is the uniquely best answer, not C.\\n\\nKey stem clues: 3‑month-old with intractable seizures, hypotonia, regression, MRI basal ganglia changes and low plasma creatine, asking: “Which test provides the most specific diagnosis for GAMT deficiency?” This wording targets the definitive diagnostic test for a specific inborn error, not just a sensitive biomarker.\\n\\nMedical/logical analysis: For a specific enzymatic deficiency, current standard is molecular confirmation (GAMT gene sequencing) or enzyme assay. CSF guanidinoacetate is indeed a sensitive and relatively specific biomarker for GAMT deficiency among creatine deficiency syndromes, but it remains an indirect metabolite test and is not as “most specific” as identifying a pathogenic GAMT variant. The rationale’s claim that sequencing is less specific because it may miss some variants conflates sensitivity with specificity. Among the listed options, D (GAMT gene sequencing) best answers “most specific diagnosis.” CSF GAA (C) is important and highly suggestive but not the most specific confirmatory test.\\n\\nMinimal fix: Either change the stem to “most sensitive biomarker for GAMT deficiency” or change the keyed answer to D and adjust the explanation to emphasize molecular confirmation as the most specific test.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed – D is the uniquely best answer, not C.\n\nKey stem clues: 3‑month-old with intractable seizures, hypotonia, regression, MRI basal ganglia changes and low plasma creatine, asking: “Which test provides the most specific diagnosis for GAMT deficiency?” This wording targets the definitive diagnostic test for a specific inborn error, not just a sensitive biomarker.\n\nMedical/logical analysis: For a specific enzymatic deficiency, current standard is molecular confirmation (GAMT gene sequencing) or enzyme assay. CSF guanidinoacetate is indeed a sensitive and relatively specific biomarker for GAMT deficiency among creatine deficiency syndromes, but it remains an indirect metabolite test and is not as “most specific” as identifying a pathogenic GAMT variant. The rationale’s claim that sequencing is less specific because it may miss some variants conflates sensitivity with specificity. Among the listed options, D (GAMT gene sequencing) best answers “most specific diagnosis.” CSF GAA (C) is important and highly suggestive but not the most specific confirmatory test.\n\nMinimal fix: Either change the stem to “most sensitive biomarker for GAMT deficiency” or change the keyed answer to D and adjust the explanation to emphasize molecular confirmation as the most specific test.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-005", "question": "A 58-year-old develops progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia over 18 months. CSF shows mild lymphocytic pleocytosis. Which antibody and pathological finding are most characteristic?", "options": ["Anti-Hu; neuronal nuclear inclusions", "Anti-NMDA receptor; perivascular lymphocytic cuffing", "Anti-IgLON5; tau deposition in brainstem and hypothalamus", "Anti-LGI1; faciobrachial dystonic seizures", "Anti-GAD65; cerebellar Purkinje cell loss"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease presents with sleep dysfunction (non-REM parasomnia, obstructive apnea) and bulbar symptoms, distinct from other autoimmune encephalitides. Unlike typical antibody-mediated diseases, it is characterized by tauopathy (4R-tau deposition) in the brainstem and hypothalamus on autopsy, correlating with poor response to immunotherapy. Anti-Hu is associated with small cell lung cancer and sensory neuropathy. Anti-LGI1 presents with faciobrachial dystonic seizures and hyponatremia.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 58-year-old with progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia over 18 months, plus CSF mild lymphocytic pleocytosis. This constellation, particularly sleep-related non-REM parasomnia and obstructive apnea with bulbar and gait involvement, is characteristic of anti-IgLON5 disease, a neurodegenerative/autoimmune tauopathy predominantly affecting brainstem and hypothalamus. The keyed answer (C) correctly links anti-IgLON5 with tau deposition in brainstem and hypothalamus.\\nAlternative choices: Anti-Hu typically causes paraneoplastic sensory neuronopathy and encephalomyelitis, not a chronic parasomnia/OSA syndrome. Anti-NMDA receptor encephalitis presents with psychiatric symptoms, seizures, dyskinesias, autonomic instability, not isolated parasomnia/OSA with chronic gait ataxia. Anti-LGI1 is associated with faciobrachial dystonic seizures and limbic encephalitis, not this sleep-bulbar phenotype. Anti-GAD65 can cause cerebellar ataxia and stiff-person syndrome, but not the prominent parasomnia/OSA pattern or characteristic tau pathology.\\nMain medical accuracy issues: None significant; the description of anti-IgLON5 as a tauopathy with 4R-tau in brainstem/hypothalamus and poor immunotherapy response is accurate.\\nMinimal fix: Option B’s pathology (“perivascular lymphocytic cuffing”) is nonspecific; specifying classic anti-NMDA histopathology or omitting pathology there would improve precision but is not required for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 58-year-old with progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia over 18 months, plus CSF mild lymphocytic pleocytosis. This constellation, particularly sleep-related non-REM parasomnia and obstructive apnea with bulbar and gait involvement, is characteristic of anti-IgLON5 disease, a neurodegenerative/autoimmune tauopathy predominantly affecting brainstem and hypothalamus. The keyed answer (C) correctly links anti-IgLON5 with tau deposition in brainstem and hypothalamus.\nAlternative choices: Anti-Hu typically causes paraneoplastic sensory neuronopathy and encephalomyelitis, not a chronic parasomnia/OSA syndrome. Anti-NMDA receptor encephalitis presents with psychiatric symptoms, seizures, dyskinesias, autonomic instability, not isolated parasomnia/OSA with chronic gait ataxia. Anti-LGI1 is associated with faciobrachial dystonic seizures and limbic encephalitis, not this sleep-bulbar phenotype. Anti-GAD65 can cause cerebellar ataxia and stiff-person syndrome, but not the prominent parasomnia/OSA pattern or characteristic tau pathology.\nMain medical accuracy issues: None significant; the description of anti-IgLON5 as a tauopathy with 4R-tau in brainstem/hypothalamus and poor immunotherapy response is accurate.\nMinimal fix: Option B’s pathology (“perivascular lymphocytic cuffing”) is nonspecific; specifying classic anti-NMDA histopathology or omitting pathology there would improve precision but is not required for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-006", "question": "During VV-ECMO for severe ARDS, the circuit suddenly shows extensive air with the patient becoming pulseless. What is the immediate management step?", "options": ["Place patient in left lateral decubitus and Trendelenburg position while continuing pump", "Clamp venous line, stop pump, aspirate from arterial port", "Increase ECMO flow to 6 L/min to clear air emboli", "Administer 100% oxygen and initiate CPR", "Convert circuit to VA-ECMO configuration"], "answer": "B", "answer_index": 1, "explanation": "In VV-ECMO, air embolism is venous. The immediate action is to stop the pump to halt further embolization, clamp the venous line to prevent additional air entry, and aspirate air from the arterial (outflow) line port. Durant's position is ineffective for venous emboli. Increasing pump flow worsens embolization. CPR is secondary to circuit management. Configuration change does not address the acute air emergency.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Patient on VV-ECMO for severe ARDS; circuit suddenly shows extensive air; patient becomes pulseless; question asks for the immediate management step. This clearly describes a massive air entrainment into the ECMO circuit with hemodynamic collapse. The key emergency action is to stop further air delivery and attempt to remove air from the circuit.\\nOption B—clamp venous line, stop pump, aspirate from the arterial (outflow) port—matches standard ECMO emergency management: isolate source, stop pump to prevent further embolization, and aspirate air from the highest-risk line. That is correctly prioritized over CPR, which is secondary and largely ineffective if the circuit is actively pushing air.\\nOption A is inappropriate because continuing the pump propagates air; Durant’s position is not the primary intervention in ECMO circuit air. Option C worsens embolization. Option D is partially appropriate (100% O2/CPR) but not the immediate circuit control step, so inferior to B. Option E (convert to VA) is irrelevant and dangerous in the moment.\\nMain medical issues: Minor simplification (air may be arterialized via oxygenator), but not misleading.\\nMinimal fix: Explicitly state “massive air entrainment into the ECMO circuit is seen” to reinforce the scenario.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Patient on VV-ECMO for severe ARDS; circuit suddenly shows extensive air; patient becomes pulseless; question asks for the immediate management step. This clearly describes a massive air entrainment into the ECMO circuit with hemodynamic collapse. The key emergency action is to stop further air delivery and attempt to remove air from the circuit.\nOption B—clamp venous line, stop pump, aspirate from the arterial (outflow) port—matches standard ECMO emergency management: isolate source, stop pump to prevent further embolization, and aspirate air from the highest-risk line. That is correctly prioritized over CPR, which is secondary and largely ineffective if the circuit is actively pushing air.\nOption A is inappropriate because continuing the pump propagates air; Durant’s position is not the primary intervention in ECMO circuit air. Option C worsens embolization. Option D is partially appropriate (100% O2/CPR) but not the immediate circuit control step, so inferior to B. Option E (convert to VA) is irrelevant and dangerous in the moment.\nMain medical issues: Minor simplification (air may be arterialized via oxygenator), but not misleading.\nMinimal fix: Explicitly state “massive air entrainment into the ECMO circuit is seen” to reinforce the scenario.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-007", "question": "A 22-year-old with relapsed ALL receives axicabtagene ciloleucel. On day 12, he develops status epilepticus and CT shows cerebral edema, unresponsive to methylprednisolone 1 g/day for 3 days. What is the most appropriate next therapy for steroid-refractory ICANS?", "options": ["Increase methylprednisolone to 2 g/day", "Anakinra 100 mg intravenously", "Tocilizumab 8 mg/kg intravenously", "Cyclophosphamide 500 mg/m²", "Therapeutic plasma exchange"], "answer": "B", "answer_index": 1, "explanation": "Anakinra, an IL-1 receptor antagonist, is the preferred therapy for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). Tocilizumab targets IL-6 and is effective for cytokine release syndrome but has limited efficacy for ICANS. Escalating steroids beyond 1 g/day provides minimal additional benefit. Cyclophosphamide is not used for ICANS. Plasma exchange would eliminate the therapeutic CAR-T cells.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young patient with CAR-T (axicabtagene ciloleucel) for ALL; day 12 severe ICANS (status epilepticus, cerebral edema); already received high‑dose methylprednisolone 1 g/day for 3 days without response → steroid‑refractory ICANS. Current consensus and CARTOX/ASTCT guidance support IL‑1 blockade with anakinra as preferred next-line therapy in steroid‑refractory ICANS, while tocilizumab (IL‑6 blockade) is primarily for CRS and may worsen or not improve ICANS.\\nOption appraisal: A) Escalating methylprednisolone from 1 g to 2 g/day is not established to improve outcomes and is not standard next step once deemed steroid‑refractory. B) Anakinra IV is guideline‑consistent preferred therapy → best answer. C) Tocilizumab indicated for CRS rather than isolated ICANS; limited CNS benefit. D) Cyclophosphamide has no role in ICANS management. E) Therapeutic plasma exchange is not standard for ICANS and would likely remove CAR-T cells, undermining therapy.\\nMain medical accuracy issue(s): Minor—specific dosing schedule for anakinra not detailed, but route/dose given is reasonable. \\nMinimal fix: Explicitly state “severe ICANS (grade 3–4)” in the stem to align with guideline language, but this does not change best answer selection.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young patient with CAR-T (axicabtagene ciloleucel) for ALL; day 12 severe ICANS (status epilepticus, cerebral edema); already received high‑dose methylprednisolone 1 g/day for 3 days without response → steroid‑refractory ICANS. Current consensus and CARTOX/ASTCT guidance support IL‑1 blockade with anakinra as preferred next-line therapy in steroid‑refractory ICANS, while tocilizumab (IL‑6 blockade) is primarily for CRS and may worsen or not improve ICANS.\nOption appraisal: A) Escalating methylprednisolone from 1 g to 2 g/day is not established to improve outcomes and is not standard next step once deemed steroid‑refractory. B) Anakinra IV is guideline‑consistent preferred therapy → best answer. C) Tocilizumab indicated for CRS rather than isolated ICANS; limited CNS benefit. D) Cyclophosphamide has no role in ICANS management. E) Therapeutic plasma exchange is not standard for ICANS and would likely remove CAR-T cells, undermining therapy.\nMain medical accuracy issue(s): Minor—specific dosing schedule for anakinra not detailed, but route/dose given is reasonable. \nMinimal fix: Explicitly state “severe ICANS (grade 3–4)” in the stem to align with guideline language, but this does not change best answer selection.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Severe verapamil overdose with refractory shock and bradycardia; specifically asking about high‑dose insulin euglycemic therapy (HIET) dosing range and monitoring frequency. Standard toxicology guidance recommends starting HIET at about 1 unit/kg IV bolus then 1 unit/kg/hr infusion, titrating up (often up to 10 units/kg/hr) in severe CCB toxicity, with very frequent glucose checks—typically every 15–60 minutes, at least hourly initially. Option B (1–10 units/kg/hr; check glucose every hour) matches this range and monitoring focus: supraphysiologic dosing and hourly glucose monitoring to maintain euglycemia with dextrose.\\nOther options: A and C use lower infusion ranges below typical HIET dosing and under-monitor glucose or focus on potassium alone. D and E give higher or different ranges and monitor lactate or pH, which are not primary HIET targets. Thus B is clearly best.\\nMedical accuracy issues: Slight simplification—many protocols use an initial bolus, and some recommend checks more often than hourly early on—but within accepted board-style standards.\\nMinimal fix: Add mention of initial IV insulin bolus in the explanation or stem to better reflect standard HIET protocols and clarify that 1–10 units/kg/hr refers to infusion rate after bolus.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Severe verapamil overdose with refractory shock and bradycardia; specifically asking about high‑dose insulin euglycemic therapy (HIET) dosing range and monitoring frequency. Standard toxicology guidance recommends starting HIET at about 1 unit/kg IV bolus then 1 unit/kg/hr infusion, titrating up (often up to 10 units/kg/hr) in severe CCB toxicity, with very frequent glucose checks—typically every 15–60 minutes, at least hourly initially. Option B (1–10 units/kg/hr; check glucose every hour) matches this range and monitoring focus: supraphysiologic dosing and hourly glucose monitoring to maintain euglycemia with dextrose.\nOther options: A and C use lower infusion ranges below typical HIET dosing and under-monitor glucose or focus on potassium alone. D and E give higher or different ranges and monitor lactate or pH, which are not primary HIET targets. Thus B is clearly best.\nMedical accuracy issues: Slight simplification—many protocols use an initial bolus, and some recommend checks more often than hourly early on—but within accepted board-style standards.\nMinimal fix: Add mention of initial IV insulin bolus in the explanation or stem to better reflect standard HIET protocols and clarify that 1–10 units/kg/hr refers to infusion rate after bolus.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-009", "question": "A 6-month-old male infant presents with severe eczema, petechiae, recurrent otitis media, and platelet count of 30,000/µL with small platelet volume. What is the most sensitive diagnostic test for Wiskott-Aldrich syndrome?", "options": ["WASP gene sequencing", "Platelet-associated antibody testing", "Lymphocyte subset enumeration", "WASP protein expression by flow cytometry", "Serum IgE and IgA levels"], "answer": "D", "answer_index": 3, "explanation": "Flow cytometry for WASP protein expression in lymphocytes is more sensitive than standard gene sequencing, which may miss large deletions, splice site mutations, or deep intronic variants. Absent or reduced WASP protein expression confirms the diagnosis. Platelet antibodies are negative. Lymphocyte subsets are variable. IgE is elevated and IgA is low but these are nonspecific.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 6‑month-old boy with severe eczema, petechiae, recurrent infections, thrombocytopenia with small platelets—classic for Wiskott‑Aldrich syndrome. The question asks for the most sensitive diagnostic test. Among options, flow cytometric assessment of WASP protein in lymphocytes (D) directly measures expression and is recognized as more sensitive than routine sequencing alone, which can miss large deletions, splice-site, or deep intronic mutations. Laboratory phenotype (IgE/IgA), lymphocyte subsets, or platelet antibodies are nonspecific/incorrect.\\nLogical issues: None significant. The options are clearly distinguishable and one is uniquely best based on current immunology practice. Choice A (WASP gene sequencing) is important diagnostically but not “most sensitive” compared with comprehensive protein-expression screening by flow.\\nMedical accuracy: Description of WAS clinical triad and lab features is accurate. The relative sensitivity of protein expression by flow vs standard sequencing is correct and aligns with current diagnostic algorithms in many centers. No harmful or outdated recommendations.\\nMinimal fix: Specify “flow cytometric analysis of WASP protein expression in lymphocytes” in both stem and key to exactly match how the test is named in clinical practice.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 6‑month-old boy with severe eczema, petechiae, recurrent infections, thrombocytopenia with small platelets—classic for Wiskott‑Aldrich syndrome. The question asks for the most sensitive diagnostic test. Among options, flow cytometric assessment of WASP protein in lymphocytes (D) directly measures expression and is recognized as more sensitive than routine sequencing alone, which can miss large deletions, splice-site, or deep intronic mutations. Laboratory phenotype (IgE/IgA), lymphocyte subsets, or platelet antibodies are nonspecific/incorrect.\nLogical issues: None significant. The options are clearly distinguishable and one is uniquely best based on current immunology practice. Choice A (WASP gene sequencing) is important diagnostically but not “most sensitive” compared with comprehensive protein-expression screening by flow.\nMedical accuracy: Description of WAS clinical triad and lab features is accurate. The relative sensitivity of protein expression by flow vs standard sequencing is correct and aligns with current diagnostic algorithms in many centers. No harmful or outdated recommendations.\nMinimal fix: Specify “flow cytometric analysis of WASP protein expression in lymphocytes” in both stem and key to exactly match how the test is named in clinical practice.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-010", "question": "A 28-year-old develops progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over 3 years. EEG shows generalized spike-wave discharges. Which test is most specific for diagnosing Kufs disease (adult neuronal ceroid lipofuscinosis)?", "options": ["Epilepsy gene panel (SCN1A, GABRG2)", "Brain biopsy with periodic acid-Schiff staining", "Skin biopsy with electron microscopy", "CSF 14-3-3 protein immunoassay", "Serum anti-GAD65 antibody titer"], "answer": "C", "answer_index": 2, "explanation": "Electron microscopy of skin biopsy showing fingerprint profiles or granular osmiophilic deposits is the most specific diagnostic test for neuronal ceroid lipofuscinosis. Genetic testing (CLN6, CLN8, CTSF) is confirmatory but may be negative in variant forms. Brain biopsy is invasive and unnecessary. CSF 14-3-3 protein is elevated in Creutzfeldt-Jakob disease. Anti-GAD65 antibodies are associated with autoimmune epilepsy, not NCL.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young adult (28 years) with progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over several years, plus EEG with generalized spike–wave discharges, consistent with neuronal ceroid lipofuscinosis (adult Kufs variant). The question asks for the most specific diagnostic test. Option C (skin biopsy with electron microscopy) directly targets the classic ultrastructural hallmark of NCL—fingerprint or granular osmiophilic deposits—making it the single best, most specific diagnostic study among the choices.\\nOther options: A (epilepsy gene panel focused on SCN1A, GABRG2) is not directed at NCL genes (CLN6, CLN8, CTSF) and is therefore nonspecific. B (brain biopsy with PAS) is invasive and not standard; PAS is not the classic highly specific method versus EM. D (CSF 14-3-3) is a prion (CJD) marker. E (anti-GAD65) is linked with autoimmune epilepsy and stiff-person syndrome, not NCL.\\nMedical accuracy: The pathologic description and role of EM are accurate and consistent with current understanding. Minimal fix: Clarify in stem that suspected diagnosis is adult neuronal ceroid lipofuscinosis/Kufs to align fully with the teaching point.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young adult (28 years) with progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over several years, plus EEG with generalized spike–wave discharges, consistent with neuronal ceroid lipofuscinosis (adult Kufs variant). The question asks for the most specific diagnostic test. Option C (skin biopsy with electron microscopy) directly targets the classic ultrastructural hallmark of NCL—fingerprint or granular osmiophilic deposits—making it the single best, most specific diagnostic study among the choices.\nOther options: A (epilepsy gene panel focused on SCN1A, GABRG2) is not directed at NCL genes (CLN6, CLN8, CTSF) and is therefore nonspecific. B (brain biopsy with PAS) is invasive and not standard; PAS is not the classic highly specific method versus EM. D (CSF 14-3-3) is a prion (CJD) marker. E (anti-GAD65) is linked with autoimmune epilepsy and stiff-person syndrome, not NCL.\nMedical accuracy: The pathologic description and role of EM are accurate and consistent with current understanding. Minimal fix: Clarify in stem that suspected diagnosis is adult neuronal ceroid lipofuscinosis/Kufs to align fully with the teaching point.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]